About this trial
Common bile duct stones (CBDS) may be asymptomatic but can cause pancreatitis, obstructive jaundice, and/or cholangitis. In Sweden, intraoperative cholangiography (IOC) is usually performed during gallstone surgery in order to detect CBDS and proactively extract them. The intervention to extract them may, however, cause complications by itself such as pancreatitis, bleeding, or perforation. In many countries, IOC is performed selectively when CBDS are suspected preoperatively (by patient history, imaging, or blood tests), or if the anatomy is unclear. There is a knowledge gap regarding the relation between risks associated with refraining from IOC and, thus, leaving undetected CBDS in situ, or actively diagnosing and removing the stones.
To compare these risks, we propose a national multicenter randomized controlled trial. The study will be embedded in the Swedish Registry for Gallstone Surgery (GallRiks), which will include all variables for inclusion and follow-up.
Population: Patients undergoing gallstone surgery without suspicion of CBDS Intervention: IOC Control: No IOC Outcome: Readmission or reintervention (Clavien-Dindo grade ≥IIIa) related to the cholecystectomy within 12 months after the operation.
A total of 6000 patients will be recruited. The results will have the potential to provide level A evidence for routines used in gallstone surgery not only in Sweden, but also internationally.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients undergoing cholecystectomy
Disqualifiers
Preoperative suspicion of common bile duct stone
Pregnancy
Age <18 years
Preoperative suspicion of malignancy in the gallbladder or bile ducts
Trial design
Parallel
Treatments tested in this trial
Routine cholangiography
Procedure/SurgeryIntraoperative cholangiography attempted regardless of indication and anatomy
Selective cholangiograpy
Procedure/SurgeryIntraoperative cholangiography only attempted in case of uncertainty regarding anatomy
Treatment groups
Trial outcomes
Primary outcomes
Reintervention within 12 months
Readmission and/or any type of surgical, endoscopic or radiological reintervention (corresponding to Clavien-Dindo grade 3a or higher), related to the cholecystectomy within 12 months after the cholecystectomy
Secondary outcomes
Procedure time
Time required to complete the cholecystectomy
Mortality
Death within one year after surgery
Hospital stay
Cumulative hospital stay, including all admissions within one year after surgery
Health-related quality of life
Health-related quality of life assessed with SF-36
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Karolinska Institutet
Lead sponsor
Research department, Ersta Hospital
Collaborator
Stockholm South General Hospital
Collaborator